CCL

Összesen 9 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM006064
035-os BibID:WOS:A1996UY72200007
Első szerző:Bacsó Zsolt (biofizikus)
Cím:Changes in membrane potential of target cells promotes cytotoxic activity of effector T lymphocytes / Zsolt Bacsó, János Matkó, János Szöllősi, Rezső Gáspár, Sándor Damjanovich
Dátum:1996
Megjegyzések:The effector function of CD8+ lymphocytes depends on recognition by the TcR-CD3 complex of an oligopeptide presented by an MHC class I molecule on target cells. Recently it has been shown that MHC class I molecules change their conformation upon depolarization of human B lymphoblastoid JY cells. We studied here the effects of changes in membrane potential of target cells on the function of cytotoxic T lymphocytes (CTL). Selective alterations of plasma membrane potential of JY target cells were achieved by treatments with specific ionophore molecules as well as with Na(+)-K(+)-ATPase inhibitor, while the cytotoxic lymphocytes were not influenced. The plasma membrane was depolarized by gramicidin D and ouabain, while hyperpolarization was induced by valinomycin treatment. Alterations of the resting membrane potential of target cells in both direction resulted in an enhanced cytotoxic activity. The observed changes in cytolytic activities of cytotoxic T effectors may have a more general biological significance, namely apoptotic cells become depolarized after a given time, moreover neoplastic and virus infected cells also frequently show decreased membrane potential. A more efficient recognition of these cells by CTL is supposed to enhance the efficiency of their elimination, as well.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Cytotoxicity,Immunologic
Human
Hungary
immunology
Lymphocytes
Membrane Potentials
Support,Non-U.S.Gov't
T-Lymphocytes
T-Lymphocytes,Cytotoxic
Tumor Cells,Cultured
Valinomycin
egyetemen (Magyarországon) készült közlemény
Megjelenés:Immunology Letters. - 51 : 3 (1996), p. 175-180. -
További szerzők:Matkó János (1952-) (biológus) Szöllősi János (1953-) (biofizikus) Gáspár Rezső (1944-) (biofizikus) Damjanovich Sándor (1936-2017) (biofizikus)
Internet cím:elektronikus változat
DOI
Borító:

2.

001-es BibID:BIBFORM004703
035-os BibID:(scopus)0037013728 (wos)000176059200014
Első szerző:Damjanovich Sándor (biofizikus)
Cím:Does mosaicism of the plasma membrane at molecular and higher hierarchical levels in human lymphocytes carry information on the immediate history of cells? / Damjanovich, S., Matyus, L., Damjanovich, L., Bene, L., Jenei, A., Matko, J., Gaspar, R., Szollosi, J.
Dátum:2002
Megjegyzések:A theoretical analysis of experimental data is presented in this mini-review on non-random homo- and hetero-associations of cell surface receptors, which can be recruited in the plasma membrane or at the surface of the rough endoplasmic reticulum during the protein synthesis. In the latter case, the likely genetic origin of these supramolecular formations is analyzed, contrasting this concept to the mobility of the cell surface proteins. A model is offered which, on the one hand, allows the mobility in a restricted way even among microdomain-confined receptor proteins through 'swapping partners'. On the other hand, the lack of mixing molecular components of protein clusters will be analyzed, when homo-and hetero-associations are studied through cell fusion experiments. The most frequently studied cell surface patterns have included lipid raft organized HLA class I and II, ICAM-1, tetraspan molecules, IL2 and IL15 and other receptors, as well. On the contrary coated pit-associated transferrin receptors would not mix with the above lipid raft associated receptor patterns, although transferrin receptor would readily oligomerize into homo-associates. The functional consequences of these superstructures are also analyzed. On the 30th anniversary of the Singer-Nicolson fluid mosaic membrane model one has to pay tribute to the authors, because of their deep insight emphasizing also the mosaicism of the membranes in general and that of the plasma membrane, in particular.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
analysis
Biophysics
Cell Fusion
Cells
Human
Hungary
Lymphocytes
Proteins
egyetemen (Magyarországon) készült közlemény
Megjelenés:Immunology Letters. - 82 : 1-2 (2002), p. 93-99. -
További szerzők:Mátyus László (1956-) (biofizikus) Damjanovich László (1960-) (általános sebész) Bene László (1963-) (biofizikus) Jenei Attila (1966-) (biofizikus) Matkó János (1952-) (biológus) Gáspár Rezső (1944-) (biofizikus) Szöllősi János (1953-) (biofizikus)
Internet cím:DOI
elektronikus változat
Borító:

3.

001-es BibID:BIBFORM010350
035-os BibID:(scopus)67349251235 (wos)000267233000008
Első szerző:Friedländer Elza (biofizikus)
Cím:Corrigendum to ?ErbB-directed immunotherapy: Antibodies in current practice and promising new agents" [Immunol. Lett. 116/2 (2008) 126-140] / Friedlander, E., Barok, M., Szollosi, J., Vereb, G.
Dátum:2009
ISSN:0165-2478
Tárgyszavak:Orvostudományok Elméleti orvostudományok hozzászólás
folyóiratcikk
Antibodies
Megjelenés:Immunology Letters. - 124 : 1 (2009), p. 55-56. -
További szerzők:Barok Márk (1976-) (biofizikus) Szöllősi János (1953-) (biofizikus) Vereb György (1965-) (absztraktok, könyvfejezetek)
Internet cím:DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

4.

001-es BibID:BIBFORM005181
035-os BibID:(scopus)40149107884 (wos)000255092200005
Első szerző:Friedländer Elza (biofizikus)
Cím:ErbB-directed immunotherapy : antibodies in current practice and promising new agents / Elza Friedländer, Márk Barok, János Szöllősi, György Vereb
Dátum:2008
Megjegyzések:The ErbB family is well known for its significance in oncogenesis. As bad prognostic markers, overexpressed or mutated ErbB1 and ErbB2 have an important role in the molecular diagnosis of various cancers, but as membrane proteins, expressed often selectively in tumor tissues, they can be targeted with kinase inhibitors or therapeutic antibodies. In addition to trastuzumab, the first humanized antibody that was approved for the therapy of solid tumors by the FDA, now many humanized antibodies are in late clinical trials, or already approved. Conjugation of antibodies with radioactive isotopes, cytotoxic agents or liposomes loaded with chemotherapeutic drugs led to improved therapeutic efficiency over their parent "unarmed" antibodies. Novel, engineered antibody derivates with better pharmacodynamic properties are also available and allow the targeting of ErbB1 or ErbB2 positive cancers in a wider patient population. In this review, we discuss the biological and clinical background of ErbB targeting, and describe the most successful antibodies against ErbB1 (cetuximab, panitumumab, matuzumab, nimotuzumab, ICR62, mAb 528, ch806 and MDX-447) and ErbB2 (trastuzumab, pertuzumab, MDX-H210, 2B1, C6.5xscFv(NM3E2), ertumaxomab and FRP-5 derivates) that are in clinical trials or already approved, along with the various relevant conjugation and engineering strategies. Recent data pertinent to the prevalent problem of clinical resistance to treatment with trastuzumab are also discussed.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
agonists
analysis
Animal
Antibodies
Antibody conjugation
Antibody targeted delivery
Apoptosis
Biophysics
Brain
Carcinoma
Cell Line
Cell Proliferation
Cell Survival
Cells
Clinical trial
Cysteine
diagnosis
Dimerization
Down-Regulation
Drug Resistance
EGFR
Endocytosis
Engineered antibody
Epidermal Growth Factor
Epitopes
ErbB1
ErbB2
Fibroblasts
Glioblastoma
Glioma
Human
Humanized antibody
Hungary
In Vitro
Insulin
Membrane Proteins
Mice
Microscopy
Microspheres
Mutation
Necrosis
Paclitaxel
Phenotype
Phosphorylation
Prevalence
Progesterone
Proteins
radiotherapy
Research
Signal Transduction
therapy
toxicity
Trastuzumab resistance
Tumor Necrosis Factor
Tumor therapy/cancer therapy
Tyrosine
Up-Regulation
Megjelenés:Immunology Letters. - 116 : 2 (2008), p. 126-140. -
További szerzők:Barok Márk (1976-) (biofizikus) Szöllősi János (1953-) (biofizikus) Vereb György (1965-) (biofizikus, orvos)
Internet cím:elektronikus változat
DOI
elektronikus változat
Borító:

5.

001-es BibID:BIBFORM004711
035-os BibID:(scopus)0037013717 (wos)000176059200002
Első szerző:Matkó János (biológus)
Cím:Landing of immune receptors and signal proteins on lipid rafts : a safe way to be spatio-temporally coordinated? / Matko, J., Szollosi, J.
Dátum:2002
Megjegyzések:In the past decade one of the cell biology's breakthroughs was discovery of membrane microdomains (rafts, caveolae) and recognition of their important in cellular signaling and protein traffic. In the present minireview a short comprehensive overview is given about physico-chemical, structural and functional properties of rafts. In addition to the classical immunochemical techniques the latest physcial and biophysical technologies that can be used to study these microdomains are also described briefly. The funcational significance of rafts in signaling of multichain immune recognition receptors (MIRRs), the IL-2R and ErbB family factor receptors is also discussed herein together with the still open questions and future prospects of the raft hypothesis.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Hungary
immunology
Membrane Microdomains
Proteins
Megjelenés:Immunology Letters. - 82 : 1-2 (2002), p. 3-15. -
További szerzők:Szöllősi János (1953-) (biofizikus)
Internet cím:elektronikus változat
DOI
Borító:

6.

001-es BibID:BIBFORM048687
035-os BibID:PMID:22027563 WOS:000300859500001
Első szerző:Shrestha, Dilip (biológus)
Cím:Bare lymphocyte syndrome : an opportunity to discover our immune system / Shrestha Dilip, Szöllősi János, Jenei Attila
Dátum:2012
ISSN:0165-2478
Megjegyzések:Bare lymphocyte syndrome (BLS) is a rare immunodeficiency disorder manifested by the partial or complete disappearance of major histocompatibility complex (MHC) proteins from the surface of the cells. Based on this specific feature, it is categorized into three different types depending on which type of MHC protein is affected. These proteins are mainly involved in generating the effective immune responses by differentiating 'self' from 'non-self' antigens through a process referred to as antigen presentation. Investigations on BLS have immensely contributed to our understanding of the transcriptional regulation of these molecules and have led to the discovery of several important proteins of the antigen presentation pathway. Reviews on this subject consistently project type II BLS, MHC II deficiency as BLS syndrome, although literatures' document cases of other types of BLS too. Therefore, in this article, we have assembled information on the BLS syndrome to produce a systematic narration while emphasizing the importance of BLS system in studying various aspects of immune biology.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Bare lymphocyte syndrome
MHC
HLA
Transporter associated with antigen
processing
Class II trans-activator
Regulatory factor X complex
Molekuláris Medicina
Megjelenés:Immunology Letters. - 141 : 2 (2012), p. 147-157. -
További szerzők:Szöllősi János (1953-) (biofizikus) Jenei Attila (1966-) (biofizikus)
Pályázati támogatás:TÁMOP-4.2.1/B-09/1/KONV-2010-0007
TÁMOP
Membrán dinamika
K68763
Egyéb
TÁMOP-4.2.2-08/1-2008-0019
TÁMOP
TÁMOP-4.2.1/B-09/1/KONV-2010-0007
TÁMOP
Receptor tirozin kinázok mint terápiás célpontok: működésük szabályozásának, és a közöttük fellépő molekuláris kölcsönhatások vizsgálata
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

7.

001-es BibID:BIBFORM015628
Első szerző:Szöőr Árpád (orvos)
Cím:Rafts and the battleships of defense : the multifaceted microdomains for positive and negative signals in immune cells / Szoor, A., Szollosi, J., Vereb, G.
Dátum:2010
Megjegyzések:Recognition of the heterogeneity of the cell membrane was one of the most important scientific achievements in the last decades. Since coining the term "lipid rafts", continuous development of advanced microscopic and spectroscopic techniques has vastly expanded our view on these cell membrane microdomains that appear to have almost as many faces as researchers that look at them; they are variable in stability, size and composition that can change in a highly dynamic manner both by recruiting and expelling components as well as by coalescing and breaking up into smaller units. They have, however, one common feature: all eukaryotic cells present some variation of lipid rafts. Cells of the immune system are not exception to this, regardless of their lymphoid or myeloid origin their membranes show a domain structure and these domains serve to condense or reject particular transmembrane, GPI-linked and intracellularly membrane-anchored proteins as function requires. Here we provide a concise overview about the various weapons and shields that immune cells concentrate into their rafts, which have come into sight during the past years. The positive and negative regulatory roles of these microdomains are essential both in the functions of innate immunity and processes concatenated in the adaptive immune response
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
article
Biophysics
Cell Membrane
Cells
Eukaryotic Cells
Hungary
Immune System
lipid raft
Membrane Microdomains
Proteins
Research
Research Support
Support
OTKA::1
MAB::3.1
Megjelenés:Immunology Letters. - 130 : 1-2 (2010), p. 2-12. -
További szerzők:Szöllősi János (1953-) (biofizikus) Vereb György (1965-) (biofizikus, orvos)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
Borító:

8.

001-es BibID:BIBFORM006020
Első szerző:Trón Lajos (biofizikus)
Cím:Proximity measurements of cell surface proteins by fluorescence energy transfer / L. Trón, J. Szöllösi, S. Damjanovich
Dátum:1987
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
analysis
Energy Transfer
Flow Cytometry
Fluorescence
Histocompatibility Antigens
Hungary
immunology
Interleukin-2
Membrane Proteins
Receptors,Immunologic
Receptors,Interleukin-2
Spectrometry,Fluorescence
Support,Non-U.S.Gov't
Megjelenés:Immunology Letters. - 16 : 1 (1987), p. 1-9. -
További szerzők:Szöllősi János (1953-) (biofizikus) Damjanovich Sándor (1936-2017) (biofizikus)
Internet cím:elektronikus változat
Borító:

9.

001-es BibID:BIBFORM005110
035-os BibID:(scopus)33644694046 (wos)000236477900020
Első szerző:Zsebik Barbara (biofizikus)
Cím:Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1 / Zsebik, B., Citri, A., Isola, J., Yarden, Y., Szollosi, J., Vereb, G.
Dátum:2006
ISSN:165-2478 (Print)
Megjegyzések:ErbB2, a member of the EGF receptor family of tyrosine kinases is overexpressed on many tumor cells of epithelial origin and is the molecular target of trastuzumab (Herceptin), the first humanized antibody used in the therapy of solid tumors. Trastuzumab, which is thought to act, at least in part, by downregulating ErbB2 expression is only effective in approximately 30-40% of ErbB2 positive breast tumors. Geldanamycin and its derivative 17-AAG are potential antitumor agents capable of downregulating client proteins of Hsp90, including ErbB2. To investigate the ability of 17-AAG to downregulate ErbB2 in trastuzumab resistant breast cancer cells and the possibility of 17-AAG and trastuzumab potentiating each other's effect, the recently established trastuzumab resistant breast cancer cell line, JIMT-1 was compared to the known trastuzumab sensitive SKBR-3 line. Baseline and stimulus-evoked dimerization and activation levels of ErbB2, and the effects of trastuzumab and 17-AAG alone and in combination on cell proliferation and apoptosis, as well as on ErbB2 expression and phosphorylation have been measured. Baseline activation and amenability to activation and downregulation by trastuzumab was much lower in the resistant line. However, 17-AAG enhanced ErbB2 homodimerization after 5-10 min of treatment in both cell lines, and decreased proliferation with an IC50 of 70 nM for SKBR-3 and 10nM for JIMT-1. Thus, 17-AAG may be a useful drug in trastuzumab resistant ErbB2 overexpressing tumors. The antiproliferative effect of 17-AAG was positively correlated with phosphorylation and downregulation of ErbB2 and was dominated by apoptosis, although, especially at higher doses, necrosis was also present. Interestingly, IC50 values for ErbB2 downregulation and phosphorylation, in the 30-40 nM range, were not significantly different for the two cell lines. This observation and the negative correlation between resting ErbB2 levels and the antiproliferative effect of 17-AAG may indicate that activation of ErbB2 to some extent could counteract the overall cytostatic effect, especially at higher levels of ErbB2 expression. The usual therapeutic dose of trastuzumab did not change the IC50 of 17-AAG on the proliferation of either cell line, but nevertheless decreased overall ErbB2 phosphorylation and at low doses of 17-AAG further decreased cell growth in the sensitive SKBR-3, thus trastuzumab may be a good combination partner to counteract undesired activating effects of 17-AAG.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
analogs and derivatives
antagonists and inhibitors
Antibodies
Antibodies,Monoclonal
Antineoplastic Agents
Apoptosis
Benzoquinones
Biophysics
Breast Neoplasms
Cell Line
Cell Line,Tumor
Cell Proliferation
Cells
Dimerization
drug effects
Drug Resistance,Neoplasm
drug therapy
enzymology
HSP90 Heat-Shock Proteins
Humans
Hungary
Lactams,Macrocyclic
metabolism
Necrosis
pharmacology
Phosphorylation
Protein Kinase Inhibitors
Proteins
Receptor,erbB-2
Research
Rifabutin
Support
therapeutic use
therapy
Megjelenés:Immunology Letters. - 104 : 1-2 (2006), p. 146-155. -
További szerzők:Citri, Ami Isola, Jorma Yarden, Yosef Szöllősi János (1953-) (biofizikus) Vereb György (1965-) (biofizikus, orvos)
Internet cím:elektronikus változat
DOI
Borító:
Rekordok letöltése1 
Corvina könyvtári katalógus v8.2.27 © 2023 Monguz kft. Minden jog fenntartva.